Comment
doi: 10.1038/nrcardio.2017.204.
Epub 2017 Nov 30.
Vascular disease: PCSK9 inhibition in PAD
- PMID: 29188814
- DOI: 10.1038/nrcardio.2017.204
Item in Clipboard
Comment
Vascular disease: PCSK9 inhibition in PAD
Nat Rev Cardiol.
2018 Jan.
No abstract available
Comment on
-
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133605 Clinical Trial.
Similar articles
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
-
PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.Vasa. 2018 Apr;47(3):165-176. doi: 10.1024/0301-1526/a000689. Epub 2018 Feb 7. Vasa. 2018. PMID: 29412075 Review.
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.Clin Ther. 2017 Nov;39(11):2243-2259.e5. doi: 10.1016/j.clinthera.2017.09.009. Epub 2017 Oct 14. Clin Ther. 2017. PMID: 29037448
-
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Circulation. 2015. PMID: 26503748 Review.
-
Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".Circulation. 2018 Jul 10;138(2):220-221. doi: 10.1161/CIRCULATIONAHA.117.033207. Circulation. 2018. PMID: 29986969 No abstract available.
Cited by
-
Proteomic Profiling of Cryoglobulinemia.Front Immunol. 2022 May 23;13:855513. doi: 10.3389/fimmu.2022.855513. eCollection 2022. Front Immunol. 2022. PMID: 35677050 Free PMC article.
-
Preventive Therapies in Peripheral Arterial Disease.Biomedicines. 2023 Nov 27;11(12):3157. doi: 10.3390/biomedicines11123157. Biomedicines. 2023. PMID: 38137379 Free PMC article. Review.
-
Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023.Front Cardiovasc Med. 2024 Nov 22;11:1474472. doi: 10.3389/fcvm.2024.1474472. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39650150 Free PMC article.
References
-
- Circulation. 2017 Nov 13;:null - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
